DarioHealth Corp. (NASDAQ:DRIO – Get Ranking) noticed a big improve in brief curiosity within the month of September. As of September thirtieth, there was brief curiosity totalling 1,560,000 shares, a rise of 26.8% from the September fifteenth complete of 1,230,000 shares. Primarily based on a median each day quantity of 212,000 shares, the short-interest ratio is at present 7.4 days.
Institutional Inflows and Outflows
A number of hedge funds have just lately added to or lowered their stakes in DRIO. Steward Companions Funding Advisory LLC acquired a brand new place in shares of DarioHealth within the 1st quarter valued at about $25,000. FMR LLC boosted its holdings in shares of DarioHealth by 1,268.0% within the 2nd quarter. FMR LLC now owns 5,650 shares of the corporate’s inventory valued at $35,000 after shopping for an extra 5,237 shares throughout the interval. Klingman & Associates LLC purchased a brand new stake in DarioHealth within the 1st quarter valued at about $86,000. Cubist Systematic Methods LLC purchased a brand new stake in DarioHealth within the 2nd quarter valued at about $121,000. Lastly, Assenagon Asset Administration S.A. purchased a brand new stake in DarioHealth within the 2nd quarter valued at about $141,000. 46.50% of the inventory is owned by institutional buyers and hedge funds.
Analyst Upgrades and Downgrades
A lot of equities analysts have weighed in on the inventory. Cowen reduce their value goal on shares of DarioHealth from $18.00 to $14.00 and set an “outperform” ranking on the inventory in a analysis notice on Tuesday, August sixteenth. Cowen reduce their value goal on shares of DarioHealth from $18.00 to $14.00 and set an “outperform” ranking on the inventory in a analysis notice on Tuesday, August sixteenth. Lastly, Aegis reduce their value goal on shares of DarioHealth from $20.00 to $15.00 and set a “purchase” ranking on the inventory in a analysis notice on Thursday, August 18th.
DarioHealth Buying and selling Up 1.9 %
Shares of DRIO inventory traded up $0.09 throughout mid-day buying and selling on Monday, reaching $4.80. The corporate’s inventory had a buying and selling quantity of 154,597 shares, in comparison with its common quantity of 225,488. The corporate’s 50 day easy shifting common is $4.88 and its 200-day easy shifting common is $5.58. DarioHealth has a 12-month low of $3.66 and a 12-month excessive of $19.39. The corporate has a fast ratio of 5.71, a present ratio of 6.35 and a debt-to-equity ratio of 0.23. The agency has a market capitalization of $110.30 million, a PE ratio of -1.28 and a beta of 1.21.
DarioHealth (NASDAQ:DRIO – Get Ranking) final issued its earnings outcomes on Monday, August fifteenth. The corporate reported ($0.74) EPS for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.03. The enterprise had income of $6.18 million for the quarter, in comparison with the consensus estimate of $8.27 million. DarioHealth had a destructive web margin of 301.07% and a destructive return on fairness of 77.24%. Throughout the identical quarter final 12 months, the agency posted ($0.99) EPS. On common, analysis analysts predict that DarioHealth will submit -3.72 EPS for the present fiscal 12 months.
DarioHealth Firm Profile
(Get Ranking)
DarioHealth Corp. operates as a digital therapeutics firm in the US, Canada, the European Union, Australia, and New Zealand. The corporate provides Dario’s metabolic options to handle metabolic well being wants, akin to diabetes, hypertension, and weight administration; Dario Musculoskeletal, which helps to stop and deal with the commonest MSK circumstances; Dario’s behavioral well being answer that optimizes entry to evidence-based care; persistent situation administration options; DarioEngage, a proprietary care administration platform; and device-specific disposables check strip cartridges, lancets, and blood glucose monitoring techniques.
Learn Extra
This instantaneous information alert was generated by narrative science expertise and monetary knowledge from MarketBeat with a view to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial workforce previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.
Earlier than you think about DarioHealth, you will wish to hear this.
MarketBeat retains observe of Wall Road’s top-rated and finest performing analysis analysts and the shares they advocate to their shoppers every day. MarketBeat has recognized the 5 shares that high analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and DarioHealth wasn’t on the record.
Whereas DarioHealth at present has a “Purchase” ranking amongst analysts, top-rated analysts imagine these 5 shares are higher buys.
View The 5 Shares Right here
